Pharmacology
-
Parkinson’s drug shows promise as treatment for nicotine addiction in mouse model
Tobacco cessation expert, Carolyn Dresler, MD, MPA, said new evidence of cross talk between different types of acetylcholinergic receptors could be an important step for future research to determine if, and at what doses, these results could be replicated in humans.
-
Corticosteroid benefits unclear for acute ILD exacerbations
Erin Meier, MD, and Rachana Krishna, MBBS, MSCR, discuss the clinical implications of a recent meta-analysis, which suggests steroids may not help all patients with interstitial lung disease (ILD) who experience a flare.
-
GLP-1 receptor agonists for managing OSA: Practical insights from an endocrinologist-sleep specialist
Brian Wojeck, MD, MPH, outlines the clinical considerations sleep medicine specialists will increasingly need to know to treat patients with obesity-related sleep apnea.
-
Novel obesity medications open door to new era in treatment of OSA
In December 2024, the FDA approved tirzepatide, a dual GIP and GLP-1 receptor agonist previously approved for type 2 diabetes and obesity, as the first prescription medication for adults with moderate to severe OSA and obesity.
-
Study demonstrates viability of biologics for severe asthma, COPD exacerbations in eosinophilic inflammation
While larger studies are needed, Dharani K. Narendra, MD, FCCP, said the findings from the ABRA trial could be a game changer and reduce the need for glucocorticoids for some patients.
-
Exploring the evolving landscape in combination therapies for EGFR-mutated advanced NSCLC
Susan Scott, MD, discussed the findings from the MARIPOSA and FLAURA2 trials and the next steps to identify who may benefit from which regimen.
-
FDA grants clearance for SIMEOX 200 for patients with chronic lung disease
The approval offers providers an alternative to traditional airway clearance therapies for patients with chronic lung diseases such as bronchiectasis, COPD, and cystic fibrosis.
-
Navigating new ACR/CHEST guidelines for screening, monitoring, and treatment of SARD-ILD
Authors Jose R. Castellanos, MD; Anthony J. Esposito, MD; and Caroline Zhao, MD, discuss key strategies, including early screening with pulmonary function tests and high-resolution chest tomography, cautious glucocorticoid use, and personalized steroid-sparing treatment.
-
Pseudomonas infection in patients with noncystic fibrosis bronchiectasis
Pseudomonas aeruginosa is a clinically important organism that infects patients with noncystic fibrosis bronchiectasis (NCFB). In the United States, the estimated prevalence of NCFB is 213 per 100,000 across all […]